

Study of Cytotoxic Responses of Anticancer Drug Cyclophosphamide

Vivek Bandu Mohale¹, Vaishnavi Sanjay Bharade², Vaishnavi Santosh Wagh³,
Karan Amar Katariya⁴, Naved Khan⁵

Final Year B. Pharma Students, Department of Pharmaceutics^{1,2,3,4}

Associate Professor, Department of Pharmaceutics^{4,5}

Vardhaman College of Pharmacy, Koli, Karanja (Lad), Washim, Maharashtra, India

Abstract: *It is widely accepted that cancer, the second leading cause of death, is a morbidity with big impacts on the global health. In the last few years, chemo-therapeutic treatment continually induces alone most lengthy consequents, which is extremely harmful for the physiological and psychological health of the patients. In the present research, we discuss the recent techniques for employed for extraction, and quantitative determination of such compounds in pharmaceutical, and biological specimens. In the frame of this information, this review aims to provide basic principles of chromatography, spectroscopy. Anticancer drugs research and development have been largest market area in pharmaceuticals industry in terms of the numbers of project and clinical trials and spending. Our goals to improve cancer treatment by increasing our understanding of the mechanism by which anti-cancer treatments kill susceptible tumor cells. This articles provides an overview of current knowledge of anticancer drug their pharmacology, mechanism of action, uses, side effects,precautions, and contraindication. This mini review outlined the current status of anticancer drugs development and hinted the opinions of how to further increase the accuracy and efficacy of discovery for cancer treatment.*

Keywords: Anticancer Drugs, Cancer, Drug discovery

REFERENCES

- [1]. Moffat JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery - past, present and future. *Nat Rev Drug Discov.* 2014;13(8):588–602.
- [2]. Moreno L, Pearson AD. How can attrition rates be reduced in cancer drug discovery? *Expert Opin Drug Discov.* 2013;8(4):363–368.
- [3]. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. *CA Cancer J Clin.* 2014;64(1):9-29.
- [4]. Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. *Nature.* 2012;483(7391):531-533.
- [5]. Lopez-Lazaro M. How many times should we screen a chemical library to discover an anticancer drug? *Drug Discov Today.*
- [6]. Anticer drug, Saminathan Kayarohnar Aug 13,2015.
- [7]. Joyce mwatonoka, Feb18,2019.
- [8]. Cyclophosphamide by kalpanakawan Dec 29,2021.
- [9]. Skidmore, L'S (2015) mosby's dry guide For nursing students. (11th ed)
- [10]. Tomitka, K.; Takeuchi, T. On the phosphamidase reaction of tumor tissues. *Gann* 1955, 46, 333–334. [Google Scholar]
- [11]. Voelcker, G.; Haeglsperger, R. Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of “activated”cyclophosphamide (4-hydroxycyclophosphamide) (author’s transl). *Arzneimittelforschung* 1982, 32, 639–647. [Google Scholar]
- [12]. Dausman, D. Synthese von N,N-Bis-(2chloroethyl)-Phosphorsäureamid-Derivaten als Substrat für 3'-5'Exonucleasen und Untersuchungen zur Umsetzung von “aktiviertem Cyclophosphamid” mit 1,2 und 1,3 Dinukleophilen. Ph.D. Thesis, Universität Frankfurt am Main, Frankfurt, Germany, 1988.[Google Scholar]

- [13]. Voelcker, G. Enzyme Catalyzed Decomposition of 4-Hydroxycyclophosphamide. Open Conf. Proceeding J. 2017, 8, 44–51. [Google Scholar] [CrossRef][Green Version]
- [14]. Povirk, L.F.; Shuker, D.E. DNA damage and mutagenesis induced by nitrogen mustards. *Mutat. Res.* 1994, 318, 205–226. [Google Scholar] [CrossRef]
- [15]. Schwartz, P.S.; Waxman, D.J. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. *Mol. Pharmacol.* 2001, 60, 1268–1279. [Google Scholar] [CrossRef] [PubMed][Green Version]
- [16]. Brock, N. Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds. *Cancer Treat. Rep.* 1976, 60, 301–308. [Google Scholar] [PubMed]
- [17]. Brock, N.; Hohorst, H.J. The problem of specificity and selectivity of alkylating cytostatics: Studies on N-2-chlorethylamido-oxazaphosphorines. *Z. Krebsforsch* 1977, 88, 185–215. [Google Scholar]
- [18]. Peter, G.; Wagner, T.; Hohorst, H.J. Studies on 4-hydroperoxycyclophosphamide (NSC-181815): A simple preparation method and its application for the synthesis of “activated” sulfur- containing cyclophosphamide (NSC-26271) derivatives. *Cancer Treat. Rep.* 1976, 60, 429–435. [Google Scholar]
- [19]. Hohorst, H.J.; Bielicki, L.; Voelcker, G. The Enzymatic Basis of Cyclophosphamide Specificity. *Adv. Enzym. Regul.* 1986, 25, 99–122. [Google Scholar] [CrossRef]
- [20]. Low, J.E.; Borch, R.F.; Sladek, N.E. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramidate mustard and acrolein mediated by bifunctional catalysis. *Cancer Res.* 1982, 42, 830–837. [Google Scholar]
- [21]. Voelcker, G.; Pfeiffer, B.; Schnee AHohorst, H.J. Increased Antitumour Activity of mesyl-I-aldophosphamide-perhydrothiazine, in Vivo but Not in Vitro, Compared to I-aldophosphamide-perhydrothiazine. *J. Cancer Res. Clin. Oncol.* 2000, 126, 74–78. [Google Scholar]
- [22]. Cleusix, V.; Lacroix, C.; Vollenweider, S.; Duboux, M.; Le Blay, G. Inhibitory activity spectrum of reuterin produced by *Lactobacillus reuteri* against intestinal bacteria. *BMC Microbiol.* 2007, 12, 101. [Google Scholar] [CrossRef] [PubMed][Green Version]
- [23]. Wu, M.; Lee, H.; Bellas, R.E.; Schauer, S.L.; Arsur, M.; Katz, D.; FitzGerald, M.J.; Rothstein, T.L.; Sherr, D.H.; Sonenshein, G.E. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. *EMBO J.* 1996, 2, 4682–4690. [Google Scholar] [CrossRef]
- [24]. Sistigu, A.; Viaud, S.; Chaput, N.; Bracci, L.; Proietti, E.; Zitvogel, L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. *Semin. Immunopathol.* 2011, 33, 369–383. [Google Scholar] [CrossRef]
- [25]. Alexander, P.; Mikulski, Z. Differences in the Response of Leukaemia Cells in Tissue Culture to Nitrogen Mustard and to Dimethyl Myleran. *Biochem. Pharmacol.* 1961, 5, 275–282. [Google Scholar] [CrossRef]
- [26]. Iyer, C.; Kosters, A.; Sethi, G.; Kunnumakkara, A.B.; Aggarwal, B.B.; Versalovic, J. Probiotic *Lactobacillus reuteri* promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling. *Cell. Microbiol.* 2008, 10, 1442–1452. [Google Scholar] [CrossRef]
- [27]. Guerriero, J.L.; Ditsworth, D.; Catanzaro, J.M.; Sabino, G.; Furie, M.B.; Kew, R.R.; Crawford, H.C.; Zong, W.X. DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity. *J. Immunol.* 2011, 186, 3517–3526. [Google Scholar] [CrossRef][PubMed][Green Version]
- [28]. Voelcker, G. Causes and possibilities to circumvent cyclophosphamide toxicity. *Anti-Cancer Drugs* 2020, 31, 617–622. [Google Scholar] [CrossRef]
- [29]. Hutchinson L, Kirk R. High drug attrition rates- where are we going wrong? *Nat Rev Clin Oncol.* 2011;8(4):189–190.
- [30]. Hiyoshi H, Abdelhady S, Segerstrom L, Sveinbjornsson B, Nuriya M, Lundgren TK, Desfrere L, Miyakawa A, Yasui M, Kogner P, Johnsen JI, Andang M, Uhlen P. Quiescence and gammaH2AX in neuroblastoma are regulated by ouabain/Na,K-ATPase. *Br J Cancer.* 2012;106(11):1807-1815]